Get the Daily Brief
Latest Biotech News
Pfizer, Valneva to seek approval after mixed Lyme readout – 73% efficacy but statistical miss
Pfizer and Valneva said their Phase III Valor trial showed the Lyme disease vaccine candidate achieved about 73% efficacy but missed a prespecified statistical criterion, a result the partners...
Apogee touts long‑interval eczema wins – durable response with three‑ and six‑month dosing
Apogee reported Phase II maintenance data showing its IL‑13 antibody zumilokibart sustained clinical benefit with dosing every three or six months. The company disclosed durable EASI‑75 responses...
Sanofi pays $180M up front for Kali trispecific – deal could top $1.2B
Sanofi struck an exclusive worldwide license for Kali Therapeutics’ trispecific T‑cell engager KT‑501, paying $180 million in up‑front and near‑term payments with more than $1 billion in...
Crossbow nets $77M Series B – funds T‑Bolt T‑cell engagers for myeloid cancers
Crossbow Therapeutics closed a $77 million Series B to advance its T‑Bolt platform and fund lead clinical work on CBX‑250, a T‑cell engager targeting relapsed or refractory myeloid malignancies....
Rivia raises $15M to scale agentic AI for clinical trials – targets Boston expansion
Swiss startup Rivia closed a $15 million Series A to develop an agentic AI platform that unifies trial data in real time and to expand in US biotech hubs, notably Boston. The company plans product...
Aardvark pauses obesity trials – entire pipeline on hold after safety review
Aardvark Therapeutics paused two Phase II trials of its oral weight‑loss candidate ARD‑201 while conducting a comprehensive data review; the decision follows a voluntary pause earlier in the...
IDT enters clinical IVD space – launches two Archer NGS library‑prep assays
Integrated DNA Technologies moved into the in vitro diagnostics market with two IVD next‑generation sequencing library‑preparation assays: Archer FusionPlex‑HT Dx and Archer VariantPlex‑HT Dx....
Oryon unveils neuron‑replacement Parkinson’s program; Ron Cohen joins as CEO
Oryon Cell Therapies emerged from stealth with Phase Ib/IIa data on an autologous neuron‑replacement therapy for Parkinson’s disease and announced new funding and leadership moves. The company...
Novartis to buy Pikavation for up to $3bn: adds mutant‑selective PI3Kα candidate
Novartis announced deals to acquire Pikavation Therapeutics and related PI3Kα programs in transactions worth up to $3 billion, including $2 billion upfront for SNV4818. The company says SNV4818 is...
Pfizer, Valneva post mixed Phase III results: >70% efficacy but trial missed primary bar
Pfizer and Valneva reported Phase III results for their Lyme disease vaccine showing roughly 70%+ efficacy but failing to meet a pre‑specified statistical threshold because fewer-than‑expected...
Apogee data show long‑acting eczema drug sustains relief: less frequent dosing works
Apogee Therapeutics released Phase II maintenance data showing its IL‑13 antibody zumilokibart maintained high response rates with dosing every three or six months. The company reported durable...
Oryon unveils autologous neuron replacement therapy – presents Phase Ib/IIa data
Oryon Cell Therapies emerged from stealth to present early clinical data for an autologous neuron replacement program in Parkinson’s disease and announced fresh funding and leadership moves. The...
Kali inks $1.2bn Sanofi deal – trispecific KT‑501 licensed for autoimmune indications
Kali Therapeutics signed a global licensing agreement with Sanofi for its trispecific T‑cell engager KT‑501 in a deal that could reach $1.2 billion. Sanofi will provide roughly $180 million in...
Rivia raises $15m – agentic AI to cut trial data review timelines
Swiss startup Rivia closed a $15 million Series A to scale an “agentic” AI platform aimed at real‑time unification and management of clinical trial data and to expand into U.S. biotech hubs,...
Study finds metformin activates genetic 'locks' – delays HIV rebound after ART
Researchers at Gladstone Institutes reported that two cellular genes act as 'locks' keeping HIV reservoirs dormant and that metformin can activate one of those mechanisms, delaying viral rebound...
Bionano reports revenue dip but narrows loss; CMS hikes OGM reimbursement
Bionano Genomics reported a 3% year‑over‑year decline in Q4 revenue and narrowed its net loss substantially versus the prior year, citing steady R&D and reduced SG&A. The company sold fewer flow...
Crossbow closes $77m Series B to advance T‑bolt T‑cell engagers
Crossbow Therapeutics raised $77 million in a Series B round to advance its T‑Bolt platform and first‑in‑class T‑cell engager CBX‑250 into and through Phase I studies for myeloid malignancies. CEO...
IDT enters IVD market with Archer FusionPlex‑HT Dx and VariantPlex‑HT Dx assays
Danaher subsidiary Integrated DNA Technologies launched two in vitro diagnostic (IVD) NGS library‑preparation assays—Archer FusionPlex‑HT Dx and Archer VariantPlex‑HT Dx—marking a strategic move...
Novartis to buy Pikavation—up to $3B for mutant‑selective PI3Kα
Novartis announced acquisitions and license moves to bolster its PI3Kα oncology portfolio, agreeing to acquire Pikavation and to pay up to $3 billion and separately committing billions to...
Pfizer, Valneva: Lyme vaccine cuts ~73% of cases — misses key statistical hurdle
Pfizer and Valneva reported Phase 3 results showing their Lyme disease vaccine reduced infections by roughly 70–73% but failed to meet the trial’s pre‑specified statistical criterion. The partners...